Halozyme Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Halozyme Therapeutics ha aumentado sus beneficios a una tasa media anual de 46.9%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 12.7% anual. Los ingresos han ido creciendo a una tasa media de 35.1% al año. La rentabilidad financiera de Halozyme Therapeutics es de 336%, y sus márgenes netos son de 34%.

Información clave

46.9%

Tasa de crecimiento de los beneficios

47.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	35.1%
Rentabilidad financiera	336.0%
Margen neto	34.0%
Próxima actualización de resultados	07 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dec 09

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Oct 24

Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today

Sep 08

Halozyme Therapeutics raises $625M through convertible senior notes due 2028

Aug 16

Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off

Aug 03

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jul 26

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Jun 10

Halozyme: Antares Pharma Bolsters Growth Prospects

May 19

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Apr 25

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Halozyme Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:HALO Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	829	282	149
30 Sep 23	781	254	127
30 Jun 23	774	234	127
31 Mar 23	705	182	145
31 Dec 22	660	202	122
30 Sep 22	581	211	120
30 Jun 22	487	366	98
31 Mar 22	472	435	53
31 Dec 21	443	403	50
30 Sep 21	463	409	47
30 Jun 21	412	229	46
31 Mar 21	331	163	44
31 Dec 20	268	129	46
30 Sep 20	200	22	48
30 Jun 20	180	-40	54
31 Mar 20	164	-80	61
31 Dec 19	196	-72	77
30 Sep 19	203	-40	71
30 Jun 19	182	-43	68
31 Mar 19	178	-51	65
31 Dec 18	152	-80	61
30 Sep 18	281	46	58
30 Jun 18	319	76	56
31 Mar 18	318	68	55
31 Dec 17	317	63	54
30 Sep 17	166	-88	51
30 Jun 17	134	-120	50
31 Mar 17	134	-116	48
31 Dec 16	147	-103	46
30 Sep 16	160	-71	44
30 Jun 16	149	-67	43
31 Mar 16	159	-37	41
31 Dec 15	135	-32	40
30 Sep 15	113	-42	38
30 Jun 15	107	-38	36
31 Mar 15	82	-57	35
31 Dec 14	75	-68	36
30 Sep 14	57	-85	37
30 Jun 14	59	-84	36
31 Mar 14	55	-91	35
31 Dec 13	55	-83	32
30 Sep 13	64	-66	30
30 Jun 13	53	-67	27

Ingresos de calidad: HALO tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (34%) de HALO son superiores a los del año pasado (30.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: HALO ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 46.9% al año.

Acelerando crecimiento: El crecimiento de los beneficios de HALO en el último año (39.3%) está por debajo de su media de 5 años (46.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de HALO en el último año (39.3%) superó al de la industria Biotechs -8.9%.

Rentabilidad financiera

Alta ROE: Aunque la rentabilidad financiera (336%) de HALO es excepcional, esta métrica está sesgada debido a su alto nivel de deuda.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Halozyme Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Recent updates

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations

President exercised options and sold US$735k worth of stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

President exercised options and sold US$601k worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Senior VP & Chief Technical Officer exercised options and sold US$544k worth of stock

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Senior VP & Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Senior VP & Chief Technical Officer notifies of intention to sell stock

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Senior VP & Chief Technical Officer notifies of intention to sell stock

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Insufficient new directors

Price target decreased by 7.1% to US$52.11

Investor sentiment deteriorates as stock falls 16%

President notifies of intention to sell stock

Independent Director recently sold US$962k worth of stock

Chief Technical Officer notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$1.1m worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

President exercised options and sold US$1.1m worth of stock

Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023

General Counsel exercised options and sold US$155k worth of stock

President exercised options and sold US$1.3m worth of stock

Independent Director recently sold US$1.7m worth of stock

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Independent Director notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

CFO & Director recently sold US$269k worth of stock

Price target increased to US$51.63

Desglose de ingresos y gastos
Beta